{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:10:47Z","timestamp":1791835847530,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiovascular diseases, including diabetic cardiomyopathy, are major causes of death in people with type 2 diabetes. Aldose reductase activity is enhanced in hyperglycemic conditions, leading to altered cardiac energy metabolism and deterioration of cardiac function with adverse remodeling. Because disturbances in cardiac energy metabolism can promote cardiac inefficiency, we hypothesized that aldose reductase inhibition may mitigate diabetic cardiomyopathy via normalization of cardiac energy metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male C57BL\/6J mice (8-week-old) were subjected to experimental type 2 diabetes\/diabetic cardiomyopathy (high-fat diet [60% kcal from lard] for 10\u00a0weeks with a single intraperitoneal injection of streptozotocin (75\u00a0mg\/kg) at 4\u00a0weeks), following which animals were randomized to treatment with either vehicle or AT-001, a next-generation aldose reductase inhibitor (40\u00a0mg\/kg\/day) for 3\u00a0weeks. At study completion, hearts were perfused in the isolated working mode to assess energy metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Aldose reductase inhibition by AT-001 treatment improved diastolic function and cardiac efficiency in mice subjected to experimental type 2 diabetes. This attenuation of diabetic cardiomyopathy was associated with decreased myocardial fatty acid oxidation rates (1.15\u2009\u00b1\u20090.19 vs 0.5\u2009\u00b1\u20090.1\u00a0\u00b5mol\u00a0min<jats:sup>\u22121<\/jats:sup>\u00a0g dry\u00a0wt<jats:sup>\u22121<\/jats:sup>\u00a0in the presence of insulin) but no change in glucose oxidation rates compared to the control group. In addition, cardiac fibrosis and hypertrophy were also mitigated via AT-001 treatment in mice with diabetic cardiomyopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Inhibiting aldose reductase activity ameliorates diastolic dysfunction in mice with experimental type 2 diabetes, which may be due to the decline in myocardial fatty acid oxidation, indicating that treatment with AT-001 may be a novel approach to alleviate diabetic cardiomyopathy in patients with diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01811-w","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T16:03:12Z","timestamp":1680019392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation"],"prefix":"10.1186","volume":"22","author":[{"given":"Keshav","family":"Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutuba G.","family":"Karwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amirhossein","family":"Tabatabaei Dakhili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory S.","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina T.","family":"Saed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Panidarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravichandran","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ussher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Lopaschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"11","key":"1811_CR1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","volume":"126","author":"RH Ritchie","year":"2020","unstructured":"Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501\u201325.","journal-title":"Circ Res"},{"issue":"4","key":"1811_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"key":"1811_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.02.011","author":"I Zlobine","year":"2016","unstructured":"Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016. https:\/\/doi.org\/10.1016\/j.bbalip.2016.02.011.","journal-title":"Biochim Biophys Acta"},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"603247","DOI":"10.3389\/fphys.2020.603247","volume":"11","author":"K Gopal","year":"2020","unstructured":"Gopal K, Chahade JJ, Kim R, Ussher JR. The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy. Front Physiol. 2020;11:603247.","journal-title":"Front Physiol"},{"issue":"9","key":"1811_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585\u2013607.","journal-title":"Nat Rev Cardiol"},{"key":"1811_CR6","doi-asserted-by":"publisher","first-page":"636267","DOI":"10.3389\/fendo.2021.636267","volume":"12","author":"S Jannapureddy","year":"2021","unstructured":"Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Front Endocrinol. 2021;12:636267.","journal-title":"Front Endocrinol"},{"issue":"2","key":"1811_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/diab.46.2.292","volume":"46","author":"R Ramasamy","year":"1997","unstructured":"Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997;46(2):292\u2013300.","journal-title":"Diabetes"},{"issue":"1","key":"1811_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0008-6363(97)00018-7","volume":"34","author":"D Paulson","year":"1997","unstructured":"Paulson D. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res. 1997;34(1):104\u201312.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"1811_CR9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1096\/fj.03-1400com","volume":"18","author":"YC Hwang","year":"2004","unstructured":"Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 2004;18(11):1192\u20139.","journal-title":"FASEB J"},{"issue":"9","key":"1811_CR10","doi-asserted-by":"publisher","first-page":"e46549","DOI":"10.1371\/journal.pone.0046549","volume":"7","author":"NH Son","year":"2012","unstructured":"Son NH, Ananthakrishnan R, Yu S, Khan RS, Jiang H, Ji R, et al. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. PLoS ONE. 2012;7(9):e46549.","journal-title":"PLoS ONE"},{"issue":"12","key":"1811_CR11","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1210\/en.2005-0938","volume":"146","author":"J Buchanan","year":"2005","unstructured":"Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146(12):5341\u20139.","journal-title":"Endocrinology"},{"issue":"8","key":"1811_CR12","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.2337\/db14-1560","volume":"64","author":"LM Le Page","year":"2015","unstructured":"Le Page LM, Rider OJ, Lewis AJ, Ball V, Clarke K, Johansson E, et al. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes. 2015;64(8):2735\u201343.","journal-title":"Diabetes"},{"issue":"4","key":"1811_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.107.150417","volume":"101","author":"GD Lopaschuk","year":"2007","unstructured":"Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101(4):335\u201347.","journal-title":"Circ Res"},{"issue":"8","key":"1811_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.2337\/db09-0011","volume":"58","author":"JR Ussher","year":"2009","unstructured":"Ussher JR, Koves TR, Jaswal JS, Zhang L, Ilkayeva O, Dyck JR, et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes. 2009;58(8):1766\u201375.","journal-title":"Diabetes"},{"issue":"10","key":"1811_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/0026-0495(92)90283-G","volume":"41","author":"A Kashiwagi","year":"1992","unstructured":"Kashiwagi A, Obata T, Suzaki M, Takagi Y, Kida Y, Ogawa T, et al. Increase in cardiac muscle fructose content in streptozotocin-induced diabetic rats. Metabolism. 1992;41(10):1041\u20136.","journal-title":"Metabolism"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fcvm.2020.00012","volume":"7","author":"N Kaludercic","year":"2020","unstructured":"Kaludercic N, Di Lisa F. Mitochondrial ROS formation in the pathogenesis of diabetic cardiomyopathy. Front Cardiovasc Med. 2020;7:12.","journal-title":"Front Cardiovasc Med"},{"issue":"Supplement 1","key":"1811_CR17","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.2337\/diabetes.53.2007.S110","volume":"53","author":"K Green","year":"2004","unstructured":"Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004;53(Supplement 1):S110\u20138.","journal-title":"Diabetes"},{"key":"1811_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.02.098","author":"M Almutairi","year":"2020","unstructured":"Almutairi M, Gopal K, Greenwell AA, Young A, Gill R, Aburasayn H, et al. The GLP-1R agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy. Can J Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.cjca.2020.02.098.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1811_CR19","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.celrep.2021.108935","volume":"35","author":"K Gopal","year":"2021","unstructured":"Gopal K, Al Batran R, Altamimi TR, Greenwell AA, Saed CT, Tabatabaei Dakhili SA, et al. FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity. Cell Rep. 2021;35(1):108935.","journal-title":"Cell Rep"},{"issue":"5","key":"1811_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.cmet.2020.03.017","volume":"31","author":"R Al Batran","year":"2020","unstructured":"Al Batran R, Gopal K, Capozzi ME, Chahade JJ, Saleme B, Tabatabaei-Dakhili SA, et al. Pimozide alleviates hyperglycemia in diet-induced obesity by inhibiting skeletal muscle ketone oxidation. Cell Metab. 2020;31(5):909\u201319.","journal-title":"Cell Metab"},{"issue":"5","key":"1811_CR21","doi-asserted-by":"publisher","first-page":"e37703","DOI":"10.1371\/journal.pone.0037703","volume":"7","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Folmes CD, Keung W, Fillmore N, Jaswal JS, Cadete VJ, et al. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS ONE. 2012;7(5):e37703.","journal-title":"PLoS ONE"},{"issue":"2","key":"1811_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/cvr\/cvs129","volume":"94","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res. 2012;94(2):359\u201369.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1811_CR23","doi-asserted-by":"publisher","first-page":"H479","DOI":"10.1152\/ajpheart.00191.2017","volume":"313","author":"K Gopal","year":"2017","unstructured":"Gopal K, Saleme B, Al Batran R, Aburasayn H, Eshreif A, Ho KL, et al. FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression. Am J Physiol Heart Circ Physiol. 2017;313(3):H479\u201390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"1811_CR24","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1073\/pnas.0711659105","volume":"105","author":"MP Blakeley","year":"2008","unstructured":"Blakeley MP, Ruiz F, Cachau R, Hazemann I, Meilleur F, Mitschler A, et al. Quantum model of catalysis based on a mobile proton revealed by subatomic x-ray and neutron diffraction studies of h-aldose reductase. Proc Natl Acad Sci USA. 2008;105(6):1844\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1811_CR25","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model. 2021;61(8):3891\u20138.","journal-title":"J Chem Inf Model"},{"issue":"1","key":"1811_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70\u201382.","journal-title":"Protein Sci"},{"issue":"10","key":"1811_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1107\/S0907444905024285","volume":"61","author":"I Hazemann","year":"2005","unstructured":"Hazemann I, Dauvergne MT, Blakeley MP, Meilleur F, Haertlein M, Van Dorsselaer A, et al. High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase. Acta Crystallogr D Biol Crystallogr. 2005;61(10):1413\u20137.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"1","key":"1811_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2013.03.009","volume":"139","author":"GV Halade","year":"2013","unstructured":"Halade GV, Jin Y-F, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013;139(1):32\u201340.","journal-title":"Pharmacol Ther"},{"key":"1811_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7008","author":"E Di Angelantonio","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015. https:\/\/doi.org\/10.1001\/jama.2015.7008.","journal-title":"JAMA"},{"issue":"2","key":"1811_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.01-0368fje","volume":"16","author":"YC Hwang","year":"2001","unstructured":"Hwang YC, Sato S, Tsai J-Y, Yan S, Bakr S, Zhang H, et al. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J. 2001;16(2):1\u201322.","journal-title":"FASEB J"},{"issue":"10","key":"1811_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/0026-0495(92)90283-G","volume":"41","author":"A Kashiwagi","year":"1992","unstructured":"Kashiwagi A, Obata T, Suzaki M, Takagi Y, Kida Y, Ogawa T, et al. Increase in cardiac muscle fructose content in streptozotocin-induced diabetic rats. Metabolism. 1992;41(10):1041\u20136.","journal-title":"Metabolism"},{"key":"1811_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.636267","author":"S Jannapureddy","year":"2021","unstructured":"Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.636267.","journal-title":"Front Endocrinol"},{"key":"1811_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-7-33","author":"Q Li","year":"2008","unstructured":"Li Q, Hwang YC, Ananthakrishnan R, Oates PJ, Guberski D, Ramasamy R. Polyol pathway and modulation of ischemia-reperfusion injury in type 2 diabetic BBZ rat hearts. Cardiovasc Diabetol. 2008. https:\/\/doi.org\/10.1186\/1475-2840-7-33.","journal-title":"Cardiovasc Diabetol"},{"issue":"25","key":"1811_CR34","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1161\/01.CIR.102.25.3046","volume":"102","author":"J Yang","year":"2000","unstructured":"Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, et al. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation. 2000;102(25):3046\u201352.","journal-title":"Circulation"},{"issue":"2","key":"1811_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2337\/diacare.27.2.448","volume":"27","author":"BF Johnson","year":"2004","unstructured":"Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care. 2004;27(2):448\u201354.","journal-title":"Diabetes Care"},{"issue":"2","key":"1811_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00044011-199815020-00005","volume":"15","author":"TP Didangelos","year":"1998","unstructured":"Didangelos TP, Athyros VG, Karamitsos DT, Papageorgiou AA, Kourtoglou GI, Kontopoulos AG. Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig. 1998;15(2):111\u201321.","journal-title":"Clin Drug Investig"},{"issue":"18","key":"1811_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1161\/01.CIR.0000127959.28627.F8","volume":"109","author":"LR Peterson","year":"2004","unstructured":"Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109(18):2191\u20136.","journal-title":"Circulation"},{"issue":"4","key":"1811_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jcmg.2008.05.004","volume":"1","author":"LR Peterson","year":"2008","unstructured":"Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging. 2008;1(4):424\u201333.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"1811_CR39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cjca.2014.04.023","volume":"30","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Fillmore N, Keung W, Mori J, Beker DL, Wagg CS, et al. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can J Cardiol. 2014;30(8):940\u20134.","journal-title":"Can J Cardiol"},{"issue":"5","key":"1811_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/aps.2010.31","volume":"31","author":"Y-j Li","year":"2010","unstructured":"Li Y-j, Wang P-h, Chen C, Zou M-h, Wang D-w. Improvement of mechanical heart function by trimetazidine in db\/db mice. Acta Pharmacol Sin. 2010;31(5):560\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1811_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358.","journal-title":"Physiol Rev"},{"key":"1811_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/11.suppl_C.30","volume":"11","author":"H Pouleur","year":"1990","unstructured":"Pouleur H. Diastolic dysfunction and myocardial energetics. Eur Heart J. 1990;11:30\u20134.","journal-title":"Eur Heart J"},{"issue":"4","key":"1811_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/cvr\/cvu156","volume":"103","author":"OA Alrob","year":"2014","unstructured":"Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res. 2014;103(4):485\u201397.","journal-title":"Cardiovasc Res"},{"issue":"7285","key":"1811_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature08778","volume":"464","author":"MD Hirschey","year":"2010","unstructured":"Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121\u20135.","journal-title":"Nature"},{"issue":"1","key":"1811_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2016.02.086","volume":"15","author":"D Thiagarajan","year":"2016","unstructured":"Thiagarajan D, Ananthakrishnan R, Zhang J, O\u2019Shea KM, Quadri N, Li Q, et al. Aldose reductase acts as a selective derepressor of PPAR\u03b3 and the retinoic acid receptor. Cell Rep. 2016;15(1):181\u201396.","journal-title":"Cell Rep"},{"issue":"29","key":"1811_CR46","doi-asserted-by":"publisher","first-page":"22293","DOI":"10.1074\/jbc.M000248200","volume":"275","author":"K Watanabe","year":"2000","unstructured":"Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor \u03b1 associated with age-dependent cardiac toxicity. J Biol Chem. 2000;275(29):22293\u20139.","journal-title":"J Biol Chem"},{"key":"1811_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yjmcc.2016.09.001","volume":"100","author":"YS Choi","year":"2016","unstructured":"Choi YS, de Mattos ABM, Shao D, Li T, Nabben M, Kim M, et al. Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. J Mol Cell Cardiol. 2016;100:64\u201371.","journal-title":"J Mol Cell Cardiol"},{"key":"1811_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.915102","author":"CL Palm","year":"2022","unstructured":"Palm CL, Nijholt KT, Bakker BM, Westenbrink BD. Short-chain fatty acids in the metabolism of heart failure\u2014rethinking the fat stigma. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.915102.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1811_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/db06-1163","volume":"56","author":"D Westermann","year":"2007","unstructured":"Westermann D, Rutschow S, J\u00e4ger S, Linderer A, Anker S, Riad A, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy. Diabetes. 2007;56(3):641\u20136.","journal-title":"Diabetes"},{"key":"1811_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0539-1","author":"SA Peeters","year":"2017","unstructured":"Peeters SA, Engelen L, Buijs J, Jorsal A, Parving HH, Tarnow L, et al. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol. 2017. https:\/\/doi.org\/10.1186\/s12933-017-0539-1.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01811-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T17:03:56Z","timestamp":1680023036000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01811-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01811-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animals received care according to the Canadian Council on Animal Care and the animal study protocol was approved by the University of Alberta Health Sciences Animal Welfare Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have declared their consent for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competing interests associated with this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}